CD274 and hypophysitis: The most frequently reported AEs are skin toxicity (45% with ipilimumab, and 35% with nivolumab and pembrolizumab), asthenia (with anti-PD1: 16–37% and anti-PDL1: 12–24%) and endocrinopathies (e.g., dysthyroidism, with incidence of 5–10%, hypophysitis, diabetes).